[Dicarbamin--an effective protector of myelodepression in combined treatment for Hodgkin's disease].
Clinical trials were carried out of the protective action of dicarbamin in 33 patients with Hodgkin's disease (13 males and 20 females, average age--31 years). They received standard chemotherapy ABVD (doxorubicin--25 mg/m2, bleomycin--10 mg/m2, vinblastine--6 mg/m2, dacarbazine--375 mg/m2, intravenously, on days 1 and 15 of each cycle, every 4 weeks. Patients suffering neutropenia after the first injection of the cytostatic drugs were given dicarbamin 100 mg/day on day 5 before a second administration. Treatment with dicarbamin continued for 15 days. Its protective effect was reported in 27 patients (81.8%). Leukocyte and granulocyte count before dicarbamin was 3.74 +/- 0.25 x 10(9)/l and 1.42 +/- 0.17 x 10(9)/l, respectively. On completion of the polychemotherapeutic cycle, the indices rose to 5.0 +/- 0.28 x 10(9)/13 and 2.49 +/- 0.25 x 10(9)/l, respectively. The beneficial effect of dicarbamin was also demonstrated by a quick recovery of leukocyte levels than in controls (p > 0.5). After the next cycle of polychemotherapy (ABVD) plus dicarbamin was given for Hodgkin's disease and grade III-IV leuko- and granulocytopenia, leukocyte and granulocyte concentrations returned back to normal which indicated the protective action of dicarbamin.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D001853:Bone Marrow / Q000187:drug effects* / Q000276:immunology; D002208:Caproates; D017024:Chemotherapy, Adjuvant; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006098:Granulocytes / Q000187:drug effects; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D020011:Protective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
D002208:Caproates; D007093:Imidazoles; D020011:Protective Agents; D001761:Bleomycin; C539419:pentanedioic acid imidazolyl ethanamide; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin